相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Recent developments in biologic therapies for the treatment of patients with systemic lupus erythematosus
Pedro L. Carreira et al.
RHEUMATOLOGY (2019)
JAK-inhibitors. New players in the field of immune-mediated diseases, beyond rheumatoid arthritis
George E. Fragoulis et al.
RHEUMATOLOGY (2019)
Short-term efficacy and safety of rituximab therapy in refractory systemic lupus erythematosus: results from the British Isles Lupus Assessment Group Biologics Register
Eoghan M. McCarthy et al.
RHEUMATOLOGY (2018)
A pivotal phase III, randomised, placebo-controlled study of belimumab in patients with systemic lupus erythematosus located in China, Japan and South Korea
Fengchun Zhang et al.
ANNALS OF THE RHEUMATIC DISEASES (2018)
Clinical predictors of response and discontinuation of belimumab in patients with systemic lupus erythematosus in real life setting. Results of a large, multicentric, nationwide study
Luca Iaccarino et al.
JOURNAL OF AUTOIMMUNITY (2018)
Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 2 trial
Daniel J. Wallace et al.
LANCET (2018)
Comprehensive assessment of the association between genes on JAK-STAT pathway (IFIH1, TYK2, IL-10) and systemic lupus erythematosus: a meta-analysis
Qiong Yin et al.
ARCHIVES OF DERMATOLOGICAL RESEARCH (2018)
Efficacy and safety of ustekinumab, an IL-12 and IL-23 inhibitor, in patients with active systemic lupus erythematosus: results of a multicentre, double-blind, phase 2, randomised, controlled study
Ronald F. van Vollenhoven et al.
LANCET (2018)
Tofacitinib Ameliorates Murine Lupus and Its Associated Vascular Dysfunction
Yasuko Furumoto et al.
ARTHRITIS & RHEUMATOLOGY (2017)
Obinutuzumab induces superior B-cell cytotoxicity to rituximab in rheumatoid arthritis and systemic lupus erythematosus patient samples
Venkat Reddy et al.
RHEUMATOLOGY (2017)
Use of Rituximab in Systemic Lupus Erythematosus: A Single Center Experience Over 14 Years
R. Aguiar et al.
ARTHRITIS CARE & RESEARCH (2017)
Pragmatic Treatment of Patients With Systemic Lupus Erythematosus With Rituximab: Long-Term Effects on Serum Immunoglobulins
Venkat Reddy et al.
ARTHRITIS CARE & RESEARCH (2017)
Anifrolumab, an Anti-Interferon-α Receptor Monoclonal Antibody, in Moderate-to-Severe Systemic Lupus Erythematosus
Richard Furie et al.
ARTHRITIS & RHEUMATOLOGY (2017)
Efficacy and Safety of Subcutaneous Belimumab in Systemic Lupus Erythematosus A Fifty-Two-Week Randomized, Double-Blind, Placebo-Controlled Study
William Stohl et al.
ARTHRITIS & RHEUMATOLOGY (2017)
Next-generation anti-CD20 monoclonal antibodies in autoimmune disease treatment
Fanny Huynh Du et al.
AUTOIMMUNITY HIGHLIGHTS (2017)
Current and future therapies for SLE: obstacles and recommendations for the development of novel treatments
Zahi Touma et al.
LUPUS SCIENCE & MEDICINE (2017)
Repeated administration of dapirolizumab pegol in a randomised phase I study is well tolerated and accompanied by improvements in several composite measures of systemic lupus erythematosus disease activity and changes in whole blood transcriptomic profiles
Chris Chamberlain et al.
ANNALS OF THE RHEUMATIC DISEASES (2017)
Efficacy and safety of subcutaneous tabalumab, a monoclonal antibody to B-cell activating factor, in patients with systemic lupus erythematosus: results from ILLUMINATE-2, a 52-week, phase III, multicentre, randomised, double-blind, placebo-controlled study
J. T. Merrill et al.
ANNALS OF THE RHEUMATIC DISEASES (2016)
A Phase II study of the efficacy and safety of rontalizumab (rhuMAb interferon-alpha) in patients with systemic lupus erythematosus (ROSE)
Kenneth C. Kalunian et al.
ANNALS OF THE RHEUMATIC DISEASES (2016)
Efficacy and safety of subcutaneous tabalumab in patients with systemic lupus erythematosus: results from ILLUMINATE-1, a 52-week, phase III, multicentre, randomised, double-blind, placebo-controlled study
D. A. Isenberg et al.
ANNALS OF THE RHEUMATIC DISEASES (2016)
Sifalimumab, an anti-interferon-α monoclonal antibody, in moderate to severe systemic lupus erythematosus: a randomised, double-blind, placebo-controlled study
Munther Khamashta et al.
ANNALS OF THE RHEUMATIC DISEASES (2016)
Interferon α kinoid induces neutralizing anti-interferon α antibodies that decrease the expression of interferon-induced and B cell activation associated transcripts: analysis of extended follow-up data from the interferon α kinoid phase I/II study
Julie Ducreux et al.
RHEUMATOLOGY (2016)
Inducible T-cell co-stimulator ligand (ICOSL) blockade leads to selective inhibition of anti-KLH IgG responses in subjects with systemic lupus erythematosus
B. A. Sullivan et al.
LUPUS SCIENCE & MEDICINE (2016)
Risk factors for osteoporosis and fragility fractures in patients with systemic lupus erythematosus
L. Carli et al.
LUPUS SCIENCE & MEDICINE (2016)
Ofatumumab treatment in lupus nephritis patients
Malena Loberg Haarhaus et al.
CLINICAL KIDNEY JOURNAL (2016)
Efficacy and safety of atacicept for prevention of flares in patients with moderate-to-severe systemic lupus erythematosus (SLE): 52-week data (APRIL-SLE randomised trial)
David Isenberg et al.
ANNALS OF THE RHEUMATIC DISEASES (2015)
Ustekinumab, an anti-IL-12/23 p40 monoclonal antibody, inhibits radiographic progression in patients with active psoriatic arthritis: results of an integrated analysis of radiographic data from the phase 3, multicentre, randomised, double-blind, placebo-controlled PSUMMIT-1 and PSUMMIT-2 trials
Arthur Kavanaugh et al.
ANNALS OF THE RHEUMATIC DISEASES (2014)
Bruton's tyrosine kinase-an integral protein of B cell development that also has an essential role in the innate immune system
Gabriela Lopez-Herrera et al.
JOURNAL OF LEUKOCYTE BIOLOGY (2014)
SYSTEMIC LUPUS ERYTHEMATOSUS IN 2013 Taking a closer look at biologic therapy for SLE
David A. Isenberg et al.
NATURE REVIEWS RHEUMATOLOGY (2014)
Why and how should we measure disease activity and damage in lupus?
Joy Feld et al.
PRESSE MEDICALE (2014)
Lupuzor/P140 peptide in patients with systemic lupus erythematosus: a randomised, double-blind, placebo-controlled phase IIb clinical trial
Robert Zimmer et al.
ANNALS OF THE RHEUMATIC DISEASES (2013)
Efficacy and Safety of Ocrelizumab in Active Proliferative Lupus Nephritis: Results From a Randomized, Double-Blind, Phase III Study
Eduardo F. Mysler et al.
ARTHRITIS AND RHEUMATISM (2013)
Down-Regulation of Interferon Signature in Systemic Lupus Erythematosus Patients by Active Immunization With Interferon α-Kinoid
Bernard R. Lauwerys et al.
ARTHRITIS AND RHEUMATISM (2013)
B-cell-targeted therapies in systemic lupus erythematosus
Vera Sau-Fong Chan et al.
CELLULAR & MOLECULAR IMMUNOLOGY (2013)
Atherosclerosis in Systemic Lupus Erythematosus
George Stojan et al.
JOURNAL OF CARDIOVASCULAR PHARMACOLOGY (2013)
Selective Inhibition of BTK Prevents Murine Lupus and Antibody-Mediated Glomerulonephritis
Andrew L. Rankin et al.
JOURNAL OF IMMUNOLOGY (2013)
Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis
George K. Bertsias et al.
ANNALS OF THE RHEUMATIC DISEASES (2012)
Btk levels set the threshold for B-cell activation and negative selection of autoreactive B cells in mice
Laurens P. Kil et al.
BLOOD (2012)
The genetics of type I interferon in systemic lupus erythematosus
Paola G. Bronson et al.
CURRENT OPINION IN IMMUNOLOGY (2012)
American College of Rheumatology Guidelines for Screening, Treatment, and Management of Lupus Nephritis
Bevra H. Hahn et al.
ARTHRITIS CARE & RESEARCH (2012)
Modulating proximal cell signaling by targeting Btk ameliorates humoral autoimmunity and end-organ disease in murine lupus
Jack Hutcheson et al.
ARTHRITIS RESEARCH & THERAPY (2012)
A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus
Richard Furie et al.
ARTHRITIS AND RHEUMATISM (2011)
Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial
Sandra V. Navarra et al.
LANCET (2011)
Assessment of a lupus nephritis cohort over a 30-year period
Sara C. Croca et al.
RHEUMATOLOGY (2011)
Fc gamma RIIB, Fc gamma RIIIB, and systemic lupus erythematosus
Heather A. Niederer et al.
YEAR IN IMMUNOLOGY 2 (2010)
IL-23: A Promising Therapeutic Target for Systemic Lupus Erythematosus
Rui-Xue Leng et al.
ARCHIVES OF MEDICAL RESEARCH (2010)
The role of B cells in lupus pathogenesis
Emil Nashi et al.
INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY (2010)
Molecular mechanism and function of CD40/CD40L engagement in the immune system
Raul Elgueta et al.
IMMUNOLOGICAL REVIEWS (2009)
Serious infections in British patients with systemic lupus erythematosus: hospitalisations and mortality
F. Goldblatt et al.
LUPUS (2009)
The Spliceosomal Phosphopeptide P140 Controls the Lupus Disease by Interacting with the HSC70 Protein and via a Mechanism Mediated by γδ T Cells
Nicolas Page et al.
PLOS ONE (2009)
Interferon alpha-induced lupus - Proof of principle
Timothy B. Niewold
JCR-JOURNAL OF CLINICAL RHEUMATOLOGY (2008)
Type I interferon receptors: Biochemistry and biological functions
Nicole A. de Weerd et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2007)
Increase of B cell-activating factor of the TNF family (BAFF) after rituximab treatment: insights into a new regulating system of BAFF production
Frederic Lavie et al.
ANNALS OF THE RHEUMATIC DISEASES (2007)
Expression and function of inducible costimulator on peripheral blood T cells in patients with systemic lupus erythematosus
JH Yang et al.
RHEUMATOLOGY (2005)
The role of CD40 in CD40L-and antibody-mediated platelet activation
F Langer et al.
THROMBOSIS AND HAEMOSTASIS (2005)
Interferon and granulopoiesis signatures in systemic lupus erythematosus blood
L Bennett et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2003)
A short course of BG9588 (anti-CD40 ligand antibody) improves serologic activity and decreases hematuria in patients with proliferative lupus glomerulonephritis
DT Boumpas et al.
ARTHRITIS AND RHEUMATISM (2003)
T cell recognition and therapeutic effect of a phosphorylated synthetic peptide of the 70K snRNP protein administered in MRL/Ipr mice
F Monneaux et al.
EUROPEAN JOURNAL OF IMMUNOLOGY (2003)
Treatment of systemic lupus erythematosus by inhibition of T cell costimulation with anti-CD154 - A randomized, double-blind, placebo-controlled trial
KC Kalunian et al.
ARTHRITIS AND RHEUMATISM (2002)
Cutting edge: Ectopic expression of CD40 ligand on B cells induces lupus-like autoimmune disease
T Higuchi et al.
JOURNAL OF IMMUNOLOGY (2002)
分享论文
